LUND, Sweden., March 30, 2023 /PRNewswire/ — Hansa Biopharma AB “Hansa” (STO TIDM: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced the release of the Annual Report 2022. Søren Tulstrup, President and CEO of Hansa Biopharma, comments: “2022 was a…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.